Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 31, 2021

Stoke Therapeutics to start Dravet syndrome therapy trial in UK

Stoke Therapeutics is set to commence a Phase I/IIa ADMIRAL study of its investigational new medicine, STK-001, for treating Dravet syndrome, a severe and progressive genetic epilepsy.

Stoke Therapeutics is set to commence a Phase I/IIa ADMIRAL study of its investigational new medicine, STK-001, for treating Dravet syndrome, a severe and progressive genetic epilepsy.

The latest development comes after the UK Medicines and Healthcare products Regulatory Agency (MHRA) authorised Stoke’s clinical trial application.

STK-001 is a proprietary antisense oligonucleotide (ASO) that could become the first disease-modifying therapy for the genetic cause of Dravet syndrome, characterised by recurrent, prolonged and refractory seizures.

The open-label, multi-centre study will evaluate the safety and tolerability of multiple doses of up to 70mg of STK-001 and characterise human pharmacokinetics.

Change in seizure frequency and quality of life measures will be included as secondary endpoints of the study.

It plans to enrol approximately 22 children and adolescents aged two to 18 years with Dravet syndrome across various clinical sites in the UK.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Stoke intends to initiate subject enrolment and dosing in the second half of this year.

Stoke Therapeutics CEO Edward Kaye said: “The ADMIRAL study complements our US-based MONARCH study, enabling the evaluation of higher dose levels of STK-001 and representing an initial step in the expansion of our global clinical development efforts.

“We look forward to working with the UK Dravet community, patients, families and healthcare providers, to add to our understanding of the potential for STK-001 to be the first disease-modifying therapy for Dravet syndrome.”

A similar MONARCH Phase I/IIa clinical trial is progressing in the US which has completed enrolment in the first two single ascending dose (SAD) cohorts (10mg and 20mg) and is currently enrolling and dosing in the third (30mg) SAD cohort.

The company anticipates preliminary safety and pharmacokinetic data from the SAD portion of the MONARCH study in the second half of this year. At present, the US Food and Drug Administration (FDA) has put a partial clinical hold on dosing above 30mg in the study.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU